Information for Health Care Professionals
FluMist is now approved for children as young as 24 months1
- Vaccinate with FluMist as soon as it is available and throughout the season
- Vaccinate at regularly scheduled visits (well-child visits, back-to-school, sports physicals)
- Help vaccine-naïve children receive their required 2 doses before flu season starts
Help protect more children by starting vaccinations early
Efficacy
View the head-to-head data showing how FluMist demonstrated significant reductions in influenza (in children) versus the flu shot, against matched and mismatched influenza strains.
The attack rates for FluMist vs the flu shot for all strains circulating during the 2004-2005 influenza season were as follows: A/New Caledonia (H1N1) (0.0% vs 1.0%), A/Wyoming (H3N2) (0% vs 0%), A/California-like (H3N2) (1.2% vs 4.9%), matched B/Yamagata lineage (1.4% vs 1.9%, NS), and mismatched B/Yamagata lineage and B/Victoria (2.1% vs 2.3%, NS), respectively.
FluMist also demonstrated substantial effectiveness in healthy adults 18 to 49 years of age.
Safety & Tolerability
View the data showing how FluMist was well-tolerated in children aged 2-17.
Do not administer FluMist to children <24 months of age due to an increased risk of hospitalization and wheezing that was observed in clinical trials.
FluMist is also well-tolerated in adults 18-49 years of age.
Ordering and Storing FluMist
Information on how to order and store FluMist.
FluMist Finder Directory Listing
List your practice in the FluMist Finder on FluMist.com, where patients can find physicians who offer FluMist in their area.
Important Safety Information
FluMist is a live attenuated influenza virus vaccine indicated for active immunization of individuals
2 - 49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
FluMist is contraindicated in individuals with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine
or with life-threatening reactions to previous influenza vaccinations, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.
Do not administer FluMist to children <24 months of age due to an increased risk of hospitalization and wheezing that was observed in clinical trials. FluMist should
not be administered to any individual with asthma and to children <5 years of age with recurrent wheezing unless the potential benefit outweighs the potential risk.
Do not administer FluMist to individuals with severe asthma or active wheezing.
If Guillain-Barré syndrome has occurred with prior influenza vaccination or if an individual is immunocompromised, the decision to give FluMist should be based on careful consideration of the potential benefits and risks. FluMist should not be administered to individuals with underlying medical conditions predisposing them to wild-type influenza infection complications unless the potential benefit outweighs the potential risk. FluMist should be given to a pregnant woman only if clearly needed.
Most common adverse reactions (occurring at ≥10% in individuals receiving FluMist and at least 5% greater than in placebo) are runny nose or nasal congestion in recipients of all ages, fever >100°F in children 2-6 years of age, and sore throat in adults.
FluMist may not protect all individuals receiving the vaccine. FluMist is for intranasal administration only.
See the complete Prescribing Information for more information.
